Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Total Liabilities (2019 - 2025)

Historic Total Liabilities for BridgeBio Pharma (BBIO) over the last 7 years, with Q3 2025 value amounting to $2.9 billion.

  • BridgeBio Pharma's Total Liabilities rose 5509.33% to $2.9 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.9 billion, marking a year-over-year increase of 5509.33%. This contributed to the annual value of $2.4 billion for FY2024, which is 2583.68% up from last year.
  • As of Q3 2025, BridgeBio Pharma's Total Liabilities stood at $2.9 billion, which was up 5509.33% from $2.9 billion recorded in Q2 2025.
  • In the past 5 years, BridgeBio Pharma's Total Liabilities ranged from a high of $2.9 billion in Q3 2025 and a low of $1.5 billion during Q1 2021
  • For the 5-year period, BridgeBio Pharma's Total Liabilities averaged around $2.0 billion, with its median value being $1.9 billion (2024).
  • As far as peak fluctuations go, BridgeBio Pharma's Total Liabilities soared by 21532.06% in 2021, and later plummeted by 127.56% in 2023.
  • BridgeBio Pharma's Total Liabilities (Quarter) stood at $1.9 billion in 2021, then fell by 0.55% to $1.9 billion in 2022, then grew by 1.12% to $1.9 billion in 2023, then rose by 25.84% to $2.4 billion in 2024, then grew by 22.89% to $2.9 billion in 2025.
  • Its Total Liabilities was $2.9 billion in Q3 2025, compared to $2.9 billion in Q2 2025 and $2.5 billion in Q1 2025.